Published in J Immunol on April 15, 2005
TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med (2008) 2.33
TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology (2008) 2.06
Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. Proc Natl Acad Sci U S A (2006) 1.87
Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation. J Clin Invest (2010) 1.50
The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. J Exp Med (2008) 1.45
Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis. Clin Exp Rheumatol (2011) 1.45
Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol (2008) 1.28
TNFSF15 is an ethnic-specific IBD gene. Inflamm Bowel Dis (2007) 1.24
Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep (2008) 1.23
TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation. Immunol Rev (2011) 1.19
Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. Eur J Immunol (2009) 1.18
IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein. PLoS One (2009) 1.15
Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis. PLoS One (2011) 1.08
Future biologic targets for IBD: potentials and pitfalls. Nat Rev Gastroenterol Hepatol (2010) 1.06
TL1A: a mediator of gut inflammation. Proc Natl Acad Sci U S A (2006) 1.02
Molecular imaging of murine intestinal inflammation with 2-deoxy-2-[18F]fluoro-D-glucose and positron emission tomography. Gastroenterology (2008) 0.99
The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4⁺ and CD8⁺ T-cell immunity. FASEB J (2012) 0.95
Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease. Mediators Inflamm (2014) 0.92
Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease. Blood (2015) 0.89
Regulation of ADAMTS-1, -4 and -5 expression in human macrophages: differential regulation by key cytokines implicated in atherosclerosis and novel synergism between TL1A and IL-17. Cytokine (2013) 0.88
The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy. Clin Dev Immunol (2011) 0.88
Age-dependent maintenance of motor control and corticostriatal innervation by death receptor 3. J Neurosci (2010) 0.88
Antigen-independent IFN-γ production by human naïve CD4 T cells activated by IL-12 plus IL-18. PLoS One (2011) 0.85
TLR8-mediated activation of human monocytes inhibits TL1A expression. Eur J Immunol (2009) 0.85
TNFSF15 Modulates Neovascularization and Inflammation. Cancer Microenviron (2012) 0.81
CD161 DEFINES EFFECTOR T CELLS THAT EXPRESS LIGHT AND RESPOND TO TL1A-DR3 SIGNALING. Eur J Microbiol Immunol (Bp) (2011) 0.81
SUSTAINED TL1A (TNFSF15) EXPRESSION ON BOTH LYMPHOID AND MYELOID CELLS LEADS TO MILD SPONTANEOUS INTESTINAL INFLAMMATION AND FIBROSIS. Eur J Microbiol Immunol (Bp) (2013) 0.80
Protective association of tumor necrosis factor superfamily 15 (TNFSF15) polymorphic haplotype with Ulcerative Colitis and Crohn's disease in an Indian population. PLoS One (2014) 0.78
TL1A induces TCR independent IL-6 and TNF-α production and growth of PLZF⁺ leukocytes. PLoS One (2014) 0.77
The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator. J Leukoc Biol (2015) 0.77
A decoy receptor 3 analogue reduces localised defects in phagocyte function in pneumococcal pneumonia. Thorax (2012) 0.76
TL1A increases expression of CD25, LFA-1, CD134 and CD154, and induces IL-22 and GM-CSF production from effector CD4 T-cells. PLoS One (2014) 0.76
On death receptor 3 and its ligands…. Immunology (2012) 0.76
Upregulation of DR3 expression in CD4⁺ T cells promotes secretion of IL-17 in experimental autoimmune uveitis. Mol Vis (2011) 0.76
Fine-mapping analysis revealed complex pleiotropic effect and tissue-specific regulatory mechanism of TNFSF15 in primary biliary cholangitis, Crohn's disease and leprosy. Sci Rep (2016) 0.75
Multiple activating and repressive cis-promoter regions regulate TNFSF15 expression in human primary mononuclear cells. Cytokine (2013) 0.75
Effect of infusion of mAbs to TNFRSF25 on graft rejection in allo-immune mice receiving autologous marrow transplantation. Immunology (2016) 0.75
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet (2007) 19.08
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest (2004) 5.39
Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet (2010) 4.65
Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology (2004) 4.42
Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet (2009) 3.65
Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology (2002) 3.21
Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology (2002) 2.66
Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol (2004) 2.53
Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. Hum Mol Genet (2010) 2.51
Biologic therapy of inflammatory bowel disease. Gastroenterology (2002) 2.49
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology (2002) 2.35
Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. Clin Gastroenterol Hepatol (2004) 2.24
Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol (2003) 2.20
A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews. Am J Hum Genet (2003) 2.17
Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol (2006) 2.14
Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol (2006) 2.12
Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol (2008) 2.09
Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol (2006) 2.06
TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology (2008) 2.06
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology (2003) 1.95
Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol (2005) 1.93
TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J Immunol (2004) 1.85
IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease. Inflamm Bowel Dis (2007) 1.71
Tumor suppressor PTEN is a physiologic suppressor of chemoattractant-mediated neutrophil functions. Blood (2007) 1.65
Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun (2010) 1.57
The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol (2007) 1.56
Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis (2007) 1.55
A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitis. Dis Colon Rectum (2009) 1.53
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut (2010) 1.53
Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation. Clin Immunol (2004) 1.52
Colorectal cancer screening and surveillance in Crohn's colitis. J Crohns Colitis (2012) 1.42
Elevated flagellin-specific immunoglobulins in Crohn's disease. Am J Physiol Gastrointest Liver Physiol (2004) 1.41
Inositol 1,3,4,5-tetrakisphosphate negatively regulates phosphatidylinositol-3,4,5- trisphosphate signaling in neutrophils. Immunity (2007) 1.33
Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis (2007) 1.33
Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol (2008) 1.28
Genetic epistasis of IL23/IL17 pathway genes in Crohn's disease. Inflamm Bowel Dis (2009) 1.27
Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.27
Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis (2010) 1.25
High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol (2004) 1.24
TNFSF15 is an ethnic-specific IBD gene. Inflamm Bowel Dis (2007) 1.24
Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep (2008) 1.23
NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology (2006) 1.20
Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's disease. Inflamm Bowel Dis (2013) 1.18
Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. Eur J Immunol (2009) 1.18
Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol (2009) 1.17
IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein. PLoS One (2009) 1.15
Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology (2012) 1.15
Co-aggregation of FcgammaRII with FcepsilonRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes. J Biol Chem (2004) 1.11
Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol (2012) 1.10
Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease. J Immunol (2007) 1.09
Cathelicidin signaling via the Toll-like receptor protects against colitis in mice. Gastroenterology (2011) 1.09
Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis. PLoS One (2011) 1.08
Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology (2006) 1.08
LIGHT expression by mucosal T cells may regulate IFN-gamma expression in the intestine. J Immunol (2004) 1.07
Cyclooxygenase-2 deficiency enhances Th2 immune responses and impairs neutrophil recruitment in hepatic ischemia/reperfusion injury. J Immunol (2008) 1.07
A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis (2004) 1.07
Future biologic targets for IBD: potentials and pitfalls. Nat Rev Gastroenterol Hepatol (2010) 1.06
Insights into IBD Pathogenesis. Curr Gastroenterol Rep (2009) 1.05
Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol (2008) 1.05
The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis (2004) 1.05
CC chemokine receptor 9 expression defines a subset of peripheral blood lymphocytes with mucosal T cell phenotype and Th1 or T-regulatory 1 cytokine profile. J Immunol (2003) 1.05
Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum (2007) 1.05
LIGHT is constitutively expressed on T and NK cells in the human gut and can be induced by CD2-mediated signaling. J Immunol (2005) 1.04
Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology? Inflamm Bowel Dis (2009) 1.03
IL23R haplotypes provide a large population attributable risk for Crohn's disease. Inflamm Bowel Dis (2008) 1.03
The antimicrobial peptide cathelicidin modulates Clostridium difficile-associated colitis and toxin A-mediated enteritis in mice. Gut (2012) 1.02
High levels of Crohn's disease-associated anti-microbial antibodies are present and independent of colitis in chronic granulomatous disease. Clin Immunol (2010) 1.01
Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum (2007) 0.99
Distinct Methylation of IFNG in the Gut. J Interferon Cytokine Res (2009) 0.99
Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflamm Bowel Dis (2011) 0.99
Molecular imaging of murine intestinal inflammation with 2-deoxy-2-[18F]fluoro-D-glucose and positron emission tomography. Gastroenterology (2008) 0.99
Microbiota activation and regulation of innate and adaptive immunity. Immunol Rev (2014) 0.98
Pattern recognition receptor and autophagy gene variants are associated with development of antimicrobial antibodies in Crohn's disease. Inflamm Bowel Dis (2012) 0.98
State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis (2005) 0.98
Certolizumab pegol. Nat Rev Drug Discov (2008) 0.98
Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol (2006) 0.98
B lymphocyte stimulator activates p38 mitogen-activated protein kinase in human Ig class switch recombination. Am J Respir Cell Mol Biol (2005) 0.97
Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm Bowel Dis (2006) 0.94
MAGI2 genetic variation and inflammatory bowel disease. Inflamm Bowel Dis (2009) 0.93
Enhancer role of STAT5 in CD2 activation of IFN-gamma gene expression. J Immunol (2004) 0.93
Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein. J Allergy Clin Immunol (2004) 0.93
Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study. Clin Gastroenterol Hepatol (2007) 0.92
Distinct IFNG methylation in a subset of ulcerative colitis patients based on reactivity to microbial antigens. Inflamm Bowel Dis (2011) 0.92
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis (2010) 0.92